Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319377 | 0.85 | ALDH1A1 (0.43) | ALDH1A1GSK3BKDM4ERXFP1ALOX12 | |
| SCHEMBL182539 | 0.81 | GSK3B (0.67) | ALDH1A1GSK3BKDM4EALOX12LMNA | |
| SCHEMBL2643929 | 0.79 | — | — | |
| SCHEMBL12683716 | 0.79 | ALDH1A1 (0.59) | ALDH1A1GSK3BKDM4ERXFP1LMNA | |
| SCHEMBL31436379 | 0.79 | GSK3B (0.64) | ALDH1A1GSK3BKDM4EALOX12LMNA | |
| SCHEMBL2511248 | 0.75 | ALDH1A1 (0.55) | ALDH1A1GSK3BKDM4ERXFP1ALOX12 | |
| Formic Acid SCHEMBL19514734 | 0.72 | GSK3B (0.54) | ALDH1A1GSK3BKDM4EALOX12LMNA | |
| SCHEMBL9204546 | 0.70 | ALDH1A1 (0.37) | ALDH1A1GSK3BKDM4ERXFP1ALOX12 | |
| SCHEMBL3077372 | 0.69 | ALDH1A1 (0.50) | ALDH1A1GSK3BKDM4ERXFP1LMNA | |
| SCHEMBL2583571 | 0.67 | CYP2A6 (0.43) | ALDH1A1KDM4EALOX12LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724786-A | Amide alkane dithiophthalimide compound, preparation method and application thereof | 四川大学 | 2023-03-03 | — | — | CN | claimed |
| JP-2007505922-A | — | — | 2007-03-15 | — | — | JP | claimed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | claimed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | claimed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | claimed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119320388-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118812532-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115335369-B | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117916368-A | Base editing of thyroxine transporter genes | 比姆医疗股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111194215-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0211805-A2 | N-(2-fluorophenyl)azolidines | CIBA-GEIGY AG (CH) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | ALDH1A1 336/4885GSK3B 3325/4885KDM4E 3440/4885 |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | ALDH1A1 231/4885GSK3B 4207/4885KDM4E 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.